The first time, the T-regulatory cell has been engineered and put into patients. We go from cohort one to cohort four, and it increases 18 fold. So we have a great range of amount of cells to add and we look forward to showing you that data next year.
Unidentified Analyst: Got it. Thank you. And on the AAV capsid, can you share what are you hoping to show or to achieve in NHP assuming that would be in the first quarter next year data?
Sandy Macrae: Amy, what do people look for in NHPs? And what does good look like?
Amy Pooler: Thanks, Sandy. I’m so excited really about the work that’s being progressed by our capsid evolution group. These capsids are essential really for delivering the genomic medicines to the right place in the nervous system and all of the engineering work that goes into solving these challenges that the brain is kind of thrown up at us. But that it’s critical to engineer that, so that we’re able to deliver the medicine. We’re looking for capsids that are able to deliver the Zinc Finger Cargo broadly across the brain, into brain regions that we know are involved in these neurological diseases that we’re targeting. And we’re able to do that to using our preclinical models and try to understand. And how that will work and into patients.
We’re unique in the company, really that is why I’m so excited about this work, because we have the outstanding Zinc Finger platform, but also, this capsid delivery effort that will allow us to create the medicines that I talked about before that are really bringing together those components. And that’s I am looking forward to sharing more about that early next year.
Sandy Macrae: So it’s about expression of the capsid throughout the brain. It’s about the activity of the Zinc Finger and it’s about consistency in areas that are clinically relevant. That’s what Google look like.
Amy Pooler: Absolutely. Yeah. Absolutely.
Unidentified Analyst: Got it. And last one from me. So on the Hemo A program, any comments on the potential of monetizing the royalty? Thank you.
Sandy Macrae: So, we can’t really comment on any financing or monetization efforts, but Nathalie, we really feel that Pfizer is doing a good job here, don’t they?
Nathalie Dubois-Stringfellow: Yes. All the patients in the pivotal trial has been dosed and really the Pfizer is still guiding to a pivotal readout expected in mid-2024 and submission of a BLA and MAA in the second half of 2024. As you know Hemophilia A as a whole and – is a big area for Pfizer and they have all the workforce to be able to advance this very efficiently into the market. So we’re very encouraged and we have regular call with our Pfizer colleague and the momentum is palpable.
Sandy Macrae: I know you’ll want to hear more about Pfizer, every signal Pfizer giving us are positive that they believe this is an important program for them. And as regards to the monetization of the royalties, if we monetize it now before the results are out, it would be an extremely discounted rate. The longer we can wait, before monetizing it, the better and more value it will be keeping it going all the way to the royalties and milestones coming directly to us would even be more valuable. And so it’s just a decision that Prathyusha and I have to make it as we finance the company.
Unidentified Analyst: Got it. That’s helpful. Thanks for all the color.
Operator: I show no further questions at this time. I would now like to turn the call back to Louise Wilkie for closing remarks.
Louise Wilkie: Thank you. And once again thanks to everyone for joining us today and for your questions. As a reminder, you can access the earnings release and the presentation on the Investor Relations section of the Sangamo website. We look forward to keeping you updated on our future developments.
Operator: This concludes today’s conference call. Thank you for participating. You may now disconnect.
